-
Analysts See Potential In The NuCana Pipeline
Monday, October 23, 2017 - 2:16pm | 251Read More...Jefferies and Citigroup initiated coverage for NuCana PLC (ADR) (NASDAQ: NCNA) Monday with a Buy rating and a price target of $25 and $23 respectively. Jefferies' analysts Eun Yang and Carmen Augustine explained that the company is focused on developing safer and more potent chemotherapies for...
